This technology is a method to identify and isolate T lymphocytes for effective therapeutics of hematological conditions.
Donor lymphocyte infusion (DLI) is a current method for treating relapsed hematological conditions. However, the treatment is less effective for acute myelogenous leukemia (AML) than for chronic myelogenous leukemia (CML), likely due to donor cell differences, but a mechanistic understanding is lacking. A clear association with increased T cell activity and cancer suppression has been established, but the advancement of diagnostic and treatment methods remains limited without targeting specific genes linked to this relationship.
This technology identifies and isolates CD8+ T lymphocytes with a specific phenotype (CD3+, CD8+, CD62L-, CD45RA+, and CD57+) for therapeutic use against leukemia cells in patients diagnosed with myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). The isolation method involves a combination of cell sorting and antibodies to create an enriched population of T lymphocytes for cancer treatment. Success has been demonstrated in cancer patients who have relapsed or undergone other failed treatment methods. When the CD8+ T lymphocyte therapy is effective, the enriched T cells exhibit high expression of specific genes such as ZNF683/HOBIT and B3GAT1/CD57, which can serve as biomarkers to evaluate and predict the effectiveness of lymphocyte-based treatments.
Patent Pending (WO/2025/0726925)
IR CU24081
Licensing Contact: Joan Martinez